Avita Medical, Inc.
Description
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
About
CEO
Mr. James M. Corbett
Employees
207
Instrument type
Depositary Receipt
Sector
Healthcare
Industry
Medical Devices
MIC code
XNCM
Address
28159 Avenue Stanford, Valencia, CA 91355, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Aug 7, 2025 | — | — | — | — |
| May 13, 2025 | — | — | — | — |
| Feb 21, 2025 | -0.35 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 8 |
| Average estimate | — | -0.56 | — | -1.06 |
| Low estimate | — | -1.26 | — | -2.72 |
| High estimate | — | 0.40 | — | 1.41 |
| Last year EPS | — | -1.11 | — | -3.55 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-73.510%
Next qtr. (Mar 2025)
49.320%
Current year
-65.820%
Next year (Dec 2025)
70.000%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total reported revenue | 50.14M | 34.42M | 29.23M | 14.26M | 3.40M |
| Cost of revenue | 7.78M | 6.04M | 5.95M | 2.97M | 789,418 |
| Gross profit | 42.36M | 28.38M | 23.28M | 11.29M | 2.61M |
| Operating expense | |||||
| Research & development | 20.82M | 13.86M | 14.82M | 9.16M | 4.97M |
| Selling general and admin | 65.63M | 45.24M | 37.06M | 48.73M | 17.17M |
| Other operating expenses | -1.43M | -3.22M | -2.06M | -3.93M | -3.68M |
| Operating income | -42.66M | -27.51M | -26.54M | -42.68M | -15.86M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 1.14M | 16,000 | 22,000 | 33,000 | 16,769 |
| Other income expense | 8.48M | 892,000 | 17,000 | 686,000 | 206,205 |
| Pretax income | -35.32M | -26.63M | -26.55M | -42.03M | -15.67M |
| Tax provision | 66,000 | 36,000 | 38,000 | 4,000 | -75,153 |
| Net income | -35.38M | -26.67M | -26.58M | -42.03M | -15.59M |
| Basic EPS | -1.40 | -1.07 | -1.17 | -2.07 | -1.95 |
| Diluted EPS | -1.40 | -1.07 | -1.17 | -2.07 | -1.95 |
| Basic average shares | 25.00M | 25.00M | 22.67M | 20.29M | 12.67M |
| Diluted average shares | 25.00M | 25.00M | 22.67M | 20.29M | 12.67M |
| EBITDA | -33.54M | -26.05M | -25.81M | -41.53M | -15.48M |
| Net income from continuing op. | -35.38M | -26.67M | -26.58M | -42.03M | -25.10M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 111.64M | 98.26M | 125.50M | 82.46M | 16.01M |
| Current assets | |||||
| Cash | — | — | — | 73.64M | 12.53M |
| Cash equivalents | — | — | — | — | 174,963 |
| Cash and cash equivalents | 22.12M | 18.16M | 110.75M | 73.64M | 12.53M |
| Other short term investments | 66.94M | 61.18M | — | — | — |
| Accounts receivable | 7.66M | 3.52M | 3.47M | 2.08M | 871,403 |
| Other receivables | 275,000 | 1.45M | 4.42M | 431,000 | 237,260 |
| Inventory | 5.60M | 2.13M | 1.65M | 1.13M | 460,856 |
| Prepaid assets | 1.41M | 1.03M | 853,000 | 915,000 | 681,967 |
| Restricted cash | — | — | 201,000 | 201,000 | 200,000 |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | 990,000 | 1.10M |
| Non current assets | |||||
| Properties | 3.65M | 1.62M | 2.13M | 2.64M | 271,000 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 2.65M | 2.07M | 1.94M | 1.60M | 1.08M |
| Construction in progress | 87,000 | 258,000 | 48,000 | 138,000 | 470,000 |
| Leases | 367,000 | 257,000 | 242,000 | 216,000 | 155,000 |
| Accumulated depreciation | -2.43M | -2.15M | -1.42M | -881,000 | -414,273 |
| Goodwill | 487,000 | 465,000 | 472,000 | 364,000 | 139,747 |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 487,000 | 465,000 | 472,000 | 364,000 | 139,747 |
| Investments and advances | — | 6.93M | — | — | — |
| Other non current assets | 2.53M | 1.24M | 1.37M | 1,000 | 125,000 |
| Total liabilities | 62.58M | 13.52M | 9.85M | 10.06M | 3.08M |
| Current liabilities | |||||
| Accounts payable | 3.79M | 3.00M | 3.12M | 4.33M | 1.19M |
| Accrued expenses | 7.97M | 6.62M | 3.32M | 2.82M | 1.32M |
| Short term debt | 895,000 | 612,000 | — | — | — |
| Deferred revenue | 201,000 | 272,000 | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | 403,937 |
| Other current liabilities | 338,000 | 184,000 | 949,000 | 560,000 | 438,000 |
| Non current liabilities | |||||
| Long term debt | 41.51M | 306,000 | 878,000 | 1.92M | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | 3.16M | — | — | — | — |
| Other non current liabilities | — | — | 503,000 | — | 42,000 |
| Shareholders equity | |||||
| Common stock | 3,000 | 3,000 | 3,000 | 3,000 | 1,863 |
| Retained earnings | -297.97M | -262.59M | -221.50M | -194.91M | -94.92M |
| Other shareholders equity | -1.89M | 7.63M | 8.26M | 8.15M | 5.08M |
| Total shareholders equity | 49.06M | 84.74M | 115.66M | 72.40M | 12.94M |
| Additional paid in capital | 350.04M | 339.83M | 328.89M | 259.17M | 102.78M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||||||
| Net Income | -35.38M | -26.67M | -26.58M | -42.03M | -25.10M | -7.91M | -8.85M | -5.81M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation | 632,000 | 568,000 | 715,000 | 465,000 | 269,000 | 68,321 | 107,354 | 62,523 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Deferred Taxes | — | — | — | — | -129,000 | -1.10M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 8.38M | 7.00M | 5.66M | 16.59M | 1.95M | 1.46M | 1.22M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 4.61M | 1.20M | 1.29M | 586,000 | 89,000 | 233,795 | — | 714,413 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Accounts Receivable | -3.30M | -985,000 | -4.98M | -582,000 | 1.97M | -1.17M | -37,684 | -385,378 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Accounts Payable | 809,000 | 282,000 | -1.33M | 2.31M | 69,000 | 280,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -4.98M | -1.40M | -1.20M | -1.31M | 808,000 | 37,881 | 236,094 | -557,514 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Cash Flow | -29.23M | -20.00M | -26.42M | -23.97M | -20.08M | -8.11M | -7.32M | -5.97M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Activities | ||||||||||||||||||||||||||||||
| Capital Expenditures | -1.38M | -452,000 | -894,000 | -590,000 | -634,143 | -226,701 | -206,469 | -22,193 | -18,179 | -41,249 | -47,383 | -48,073 | -55,402 | -44,164 | -41,515 | -57,811 | -43,514 | -79,797 | — | -91,168 | -15,575 | -4,556 | -4,260 | — | — | — | — | — | — | — |
| Net Intangibles | -66,000 | -73,000 | -280,000 | -257,000 | -127,946 | — | — | — | — | — | — | — | — | — | — | -53,646 | — | — | — | — | — | — | -58,788 | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 27,042 | — | — | — | — | -1.03M | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -78.76M | -74.36M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -538,031 | -1.98M | — | -189,974 | -35,957 | -612,741 | -450,782 | -1.66M | -2.07M |
| Sale of Investments | 81.81M | 55.56M | — | — | — | — | 299,656 | — | — | — | — | — | — | — | — | — | — | — | — | — | 473,141 | 238,950 | 677,384 | — | 262,415 | 272,996 | 944,947 | 565,443 | 16,862 | — |
| Investing Cash Flow | 1.67M | -19.26M | -894,000 | -590,000 | -634,143 | -226,701 | 93,187 | -22,193 | -18,179 | -41,249 | -47,383 | -48,073 | -55,402 | -44,164 | 169,360 | -30,769 | -43,514 | -79,797 | -286,622 | -103,452 | -576,260 | -312,563 | -1.31M | — | 1.08M | 237,039 | 332,206 | 114,661 | -1.64M | -2.07M |
| Financing Activities | ||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | 38.76M | — | — | — | — | — | — | — | — | — | — | — | 724,182 | 368,521 | — | — | — | — | — | — | — | 25,485 | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | -11,000 | -42,000 | -38,508 | -37,887 | -233,240 | — | — | — | — | — | -599,435 | -219,938 | -232,728 | -8,017 | — | — | -2,294 | — | -4,504 | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | -5.11M | -5.08M | -1.82M | -891,278 | -241,721 | -308,329 | -274,100 | — | -381,835 | -60,336 | -249,981 | -26,392 | 100,251 | — | -520,406 | -307,030 | -216,012 | -133,252 | -136,349 | — | -83,521 | — | — | — | — | — | — | -524,994 |
| Financing Cash Flow | 38.76M | — | 63.99M | 76.58M | 18.30M | 12.09M | 3.53M | 3.93M | 2.31M | — | 5.10M | -119,293 | 8.05M | 1.14M | -132,477 | -6,260 | 6.12M | 3.89M | 7.07M | 2.74M | 233,259 | 695,706 | 2.43M | 1.65M | — | — | — | 115,584 | 158,990 | 3.68M |
| Other Cash Details | ||||||||||||||||||||||||||||||
| End Cash Position | 22.12M | 18.16M | 110.95M | 73.84M | 12.65M | 6.82M | 1.81M | 1.94M | 1.41M | 2.13M | 6.02M | 5.23M | 8.41M | 2.04M | 1.74M | 5.03M | 6.48M | 3.95M | 4.38M | 1.58M | 1.37M | 2.07M | 2.03M | 1.28M | 19,811 | 53,615 | 2,908 | 8,322 | 25,052 | 1.64M |
| Income Tax Paid | 44,000 | 17,000 | 42,000 | — | — | — | — | — | -942,244 | -80,317 | -55,975 | -53,118 | -57,123 | -184,348 | -78,793 | -375,179 | -261,077 | -242,227 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 1.14M | 15,000 | 3,000 | 42,000 | 27,000 | 21,000 | 7,921 | 13 | 8 | 15,946 | 56 | 41 | 7,496 | 18,301 | 46,022 | 17,287 | — | 4,064 | — | 8,842 | — | 4 | 41 | — | — | — | — | — | 621 | — |
| Free Cash Flow | -39.46M | -19.62M | -27.08M | -23.59M | -12.72M | -8.28M | -4.29M | -3.70M | -3.07M | -4.09M | -4.16M | -2.76M | -2.00M | -898,794 | -2.39M | -2.31M | -4.78M | -4.61M | -4.13M | -2.71M | -678,643 | -188,361 | -344,391 | -390,550 | -102,891 | -185,798 | -338,005 | -245,965 | -365,196 | 20,612 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 800,719 | 7.56M | 3.05% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 712,019 | 6.72M | 2.72% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 389,203 | 3.67M | 1.48% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 260,521 | 2.46M | 0.99% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 233,831 | 2.21M | 0.89% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 144,199 | 1.36M | 0.55% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 119,385 | 1.13M | 0.46% |
| iShares Micro Cap ETF | Nov 30, 2024 | 59,149 | 558,366 | 0.23% |
| Schwab Capital Trust-Small Cap Index Fund | Oct 31, 2024 | 60,851 | 574,433 | 0.23% |
| 1290 Fds-1290 Essex Small Cap Growth Fd | Oct 31, 2024 | 55,984 | 528,488 | 0.21% |
Article
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish
AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance.
Jan 13, 2025
Article
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
Jan 10, 2025
Article
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals
On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024.
Jan 8, 2025
